Argentina

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Argentina

Argentina

Medical guidelines[edit | edit source]

National health department[edit | edit source]

Government health insurance[edit | edit source]

Private health insurance[edit | edit source]

Access to care[edit | edit source]

Ampligen (rintatolimod) has been approved for use by the Argentine Republic for severe ME/CFS as of August 23, 2016.[1]

Social security and disability benefits[edit | edit source]

Patient charities[edit | edit source]

Research[edit | edit source]

Research groups[edit | edit source]

Researchers[edit | edit source]

Clinicians[edit | edit source]

Notable patients[edit | edit source]

Deceased patients[edit | edit source]

Learn more[edit | edit source]

See also[edit | edit source]

References[edit | edit source]

  1. ↑ Inc., Hemispherx Biopharma (August 23, 2016). "Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen®) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic". GlobeNewswire News Room. Retrieved August 12, 2018.
Retrieved from "https://me-pedia.org/w/index.php?title=Argentina&oldid=190591"